1. The Illumina for discovering large structural changes in the genome.

2. A specialized genetic diagnostic lab, similar to Myriad Genetics, but focused on identifying big structural changes in a person's DNA.

• Saphyr System: An optical genome mapping solution for structural variation analysis, comprising the Saphyr instrument, Saphyr Chip, and DNA preparation/labeling kits.
• Bionano Compute Servers: Dedicated servers designed for processing and analyzing genomic data.
• NxClinical: Software providing comprehensive analysis and interpretation of genomic variants from microarray and next-generation sequencing data.
• Genetic Testing Services:
  • FirstStepDx PLUS: A chromosomal microarray service for identifying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability.
  • Fragile X Syndrome (FXS) Testing: Laboratory services specifically for diagnosing Fragile X syndrome.
  • NextStepDx PLUS: An exome sequencing test designed to identify genetic variants associated with disorders of childhood development.
  • EpiPanelDx PLUS: A genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures.
  • PGx Test: A pharmacogenomics test that identifies over 60 alleles in 11 genes relevant for drug response.

Bionano Genomics (BNGO) primarily sells its products and services to other organizations and companies, rather than directly to individual consumers. Based on the provided company description, its major customers fall into the following categories:

• Clinical Diagnostic Laboratories and Hospitals: These entities acquire Bionano's Saphyr instruments, NxClinical software, and utilize its specialized laboratory testing services (such as FirstStepDx PLUS, NextStepDx PLUS, Fragile X syndrome testing, and EpiPanelDx PLUS) for patient diagnostics, genetic variant analysis, and identification of underlying genetic causes of various conditions.
• Academic and Research Institutions: Universities and other research organizations are customers for Bionano's Saphyr systems, Saphyr Chips, Bionano Prep Kits, DNA labeling kits, and compute servers. They leverage these solutions for advanced genome analysis, structural variation studies, and understanding genetic function in a research context.
• Pharmaceutical and Biotechnology Companies: These companies likely utilize Bionano's genome analysis technologies and software solutions for their research and development activities, including drug discovery, preclinical studies, and genomic profiling.

The key risks to Bionano Genomics (BNGO) largely revolve around its financial sustainability and its ability to compete and gain market acceptance for its specialized genome analysis solutions.

1. Liquidity and Going Concern: Bionano Genomics has faced significant operating losses and negative cash flow, raising concerns about its ability to continue as a going concern without securing additional financing. The company has a limited cash runway and has frequently needed to raise capital, which can lead to dilution for existing shareholders. For instance, as of mid-2025, Bionano reportedly had only enough unrestricted cash to last through Q1 2026 without fresh funding. In Q3 2025, the company had $31.8 million in cash and investments, while still reporting a net loss of approximately $8.5 million.
2. Intense Competition and Market Adoption: The market for genome analysis is highly competitive, with established and emerging players offering various technologies. Bionano's optical genome mapping (OGM) technology, while offering unique capabilities in detecting structural variants, faces stiff competition from high-tech next-generation sequencing (NGS) firms like Illumina, Pacific Biosciences, and Oxford Nanopore, which are also advancing in structural variant detection with long-read sequencing. There are concerns about the slow market uptake of Bionano's products and the utilization of its installed systems, which directly impacts the recurring revenue from consumables and software. Scaling up from its relatively modest installed base of OGM systems presents a significant challenge.

Advancements in long-read sequencing technologies, such as those offered by companies like Pacific Biosciences (PacBio) and Oxford Nanopore Technologies. These technologies are rapidly improving in accuracy, throughput, and cost-effectiveness, and are capable of detecting large structural variations, which is the primary application area for Bionano's Saphyr optical genome mapping system. As long-read sequencing becomes more comprehensive and affordable, it presents a direct alternative and potential replacement for, or reduction in the need for, optical genome mapping for structural variation analysis.

Bionano Genomics (symbol: BNGO) operates in several significant and growing addressable markets for its main products and services.

Saphyr System (Optical Genome Mapping and Structural Variation Analysis)

• The global optical genome mapping market size was valued at approximately USD 104.1 million in 2023 and is projected to reach USD 536.4 million by 2030, growing at a compound annual growth rate (CAGR) of 26.76% from 2024 to 2030.
• Another estimate places the global optical genome mapping market at USD 131.5 million in 2023, expected to grow to USD 883.50 million by 2032, with a CAGR of 24.10% from 2024 to 2032.
• Bionano Genomics, in its 2021 Form 10-K, estimated the addressable opportunity for its Saphyr systems in discovery research and cytogenetics segments to be approximately USD 2.1 billion for instruments. Additionally, the company projected an annual recurring revenue opportunity from Saphyr consumables in the range of approximately USD 0.6 billion to USD 1.4 billion. This suggested a total addressable market for their portion of the genome analysis market between USD 2.7 billion and USD 3.5 billion at that time.
• North America held the largest share of the global optical genome mapping market, accounting for 45.07% in 2023.

NxClinical (Genomic Variant Interpretation Software for Cytogenetics and Molecular Genetics)

• The global variant interpretation software market size was valued at USD 570.1 million in 2025 and is projected to reach USD 1,782.4 million by 2034, exhibiting a CAGR of 13.07% during the forecast period.
• The global molecular cytogenetics market, which NxClinical supports, was estimated at USD 2.40 billion in 2024 and is projected to reach USD 6.39 billion by 2033, growing at a CAGR of 11.7% from 2025 to 2033.
• North America held the largest share of the global molecular cytogenetics market, with 46.01% in 2024.

Genetic Testing and Laboratory Services (FirstStepDx PLUS, Fragile X syndrome (FXS) testing, NextStepDx PLUS, EpiPanelDx PLUS, PGx test)

• The global genetic testing market size was estimated at USD 11.71 billion in 2024 and is anticipated to reach USD 39.25 billion by 2030, with a CAGR of 22.5% from 2025 to 2030.
• North America dominated the global genetic testing market with a share of 45.4% in 2024.
• For Pharmacogenomics (PGx) testing, the global pharmacogenomics technology market size was estimated at USD 7.63 billion in 2024 and is projected to reach USD 12.38 billion by 2030, growing at a CAGR of 8.1% from 2025 to 2030. North America held the largest revenue share of 36.8% in the pharmacogenomics market in 2024.
• For services related to conditions like Autism Spectrum Disorder (ASD), the global autism diagnostics market was valued at approximately USD 27.38 billion in 2024 and is projected to reach USD 35.05 billion in 2029. North America accounted for 42.06% of the global autism spectrum disorder diagnostics market in 2024.
• For epilepsy-related genetic testing, the global hereditary genetic testing market (which includes epilepsy) was initially valued at USD 24.78 billion in 2023 and is projected to surge to USD 81.95 billion by 2033. The broader epilepsy diagnosis and treatment market was estimated at USD 3.83 billion in 2024 and is anticipated to reach USD 17.6 billion by 2035, globally.

Bionano Genomics (BNGO) is expected to drive future revenue growth over the next 2-3 years through several key strategies, primarily focusing on increasing the utilization of its optical genome mapping (OGM) solutions and expanding its market reach and clinical adoption:

1. Increased Utilization of Consumables and Software: Bionano's strategic pivot emphasizes driving greater utilization of its existing installed base of OGM systems, such as Saphyr and the newer Stratys, by "routine users." This strategy aims to boost recurring revenue from high-margin nanochannel array flowcells and specialized software like VIA and NxClinical. Consumables and software constituted 72% of the product mix in Q3 2025, with sales increasing by 15% year-over-year in that quarter. The company sold 8,390 nanochannel array flowcells in Q3 2025, a 7% increase year-over-year, and 26,444 flowcells in FY 2023, marking a 72% increase over FY 2022.
2. Expansion of OGM Systems and Software Solutions: The full commercial release and adoption of new, higher-throughput instruments like the Stratys system, expected in early 2024, are anticipated to significantly increase raw data generation rates, enabling labs to process substantially more samples. Additionally, the continued adoption and enhancements of software platforms such as VIA, which streamlines data visualization, interpretation, and reporting, are crucial for supporting increased sample throughput and user efficiency.
3. Global Market Expansion and Adoption: Bionano continues to expand the global adoption of its Saphyr system, with growing utilization reported in new markets, including Japan and Africa. The increasing number of OGM publications, particularly in clinical research and cell and gene therapy, along with independent user groups advocating for OGM as an alternative to traditional cytogenetic methods, reflects broader acceptance and market penetration.
4. Favorable Reimbursement and Inclusion in Clinical Guidelines: Building strong support for OGM reimbursement and its inclusion in clinical guidelines is a key strategic pillar for Bionano. The establishment of a Category I CPT code by the American Medical Association for OGM in constitutional genetic disorders and a substantial 47% increase in the Centers for Medicare & Medicaid Services (CMS) clinical lab fee schedule for OGM testing related to hematologic malignancies (CPT code 81195) for 2026 are expected to significantly enhance revenue potential and drive wider clinical adoption.
5. Growth of the Installed Base of OGM Systems: Although the primary focus has shifted to maximizing utilization, the continued growth in the installed base of OGM systems contributes to the foundation for future consumables and software revenue. The installed base grew by 4% in Q3 2025 to 384 systems and by 36% in 2023 to 326 systems. Bionano expects to install 15 to 20 new OGM systems in full-year 2025, primarily at routine use sites, and has surpassed prior installation targets.

Share Issuance

• In January 2021, Bionano Genomics closed an underwritten public offering of approximately 38.3 million shares of common stock at $6.00 per share, resulting in gross proceeds of around $230 million.
• Also in January 2021, the company priced another underwritten public offering of approximately 29.0 million shares of its common stock at $3.05 per share, with expected gross proceeds of about $88.5 million.
• In September 2025, Bionano Genomics announced a public offering of 5 million shares with accompanying warrants, aiming to raise $10 million initially, with a potential for an additional $20 million if all warrants are fully exercised.

Capital Expenditures

• In the third quarter of 2021, Bionano Genomics invested $268K in capital expenditures, which funded long-term assets and infrastructure.
• In the 12 months prior to Q3 2025, capital expenditures were reported as $0.
• The company's "on-demand analysis" service allows customers to utilize the Saphyr System for DNA analysis without making a capital investment themselves, indicating that Bionano's capital expenditures are related to its own Saphyr systems and laboratory infrastructure.